What the $1b Roche-PathAI Deal Can Tell Clinical Lab Directors
Roche acquires a workflow rather than a company, says AI industry observer
Already a member? Log in here
Testing Trends-dtet
Diagnostics Pipeline: Expanded DPYD Test Anticipated to Make Chemotherapy Safer
Labcorp’s new genotyping test can identify gene variants that may make standard oncologic treatment deadly for some
Already a member? Log in here
Quest Diagnostics Launches Consumer-Facing AI on Its App and Portal
The company’s patients can use AI to look at trends going back five years
Already a member? Log in here
Molecular Profiling of Lung Cancer Tumors Feasible on National Scale
From – Diagnostic Testing & Emerging Technologies
Routine, nationwide molecular profiling of patients with advanced non-small cell lung cancer (NSCLC) is feasible and the screening detects actionable alterations that…
Already a member? Log in here
Viewpoints Debate Merits of Universal Tumor Sequencing
From – Diagnostic Testing & Emerging Technologies
There is universal recognition that genomic information has forever changed oncology care and is increasingly driving treatment decisions. For patients who have exhausted standard therapy or with…
Already a member? Log in here
Annual Self-Screening With FIT Effective for Colorectal Cancer Detection
...
Already a member? Log in here
More Than 1/4 of FDA’s 2015 Drug Approvals for Targeted Therapies
From – Diagnostic Testing & Emerging Technologies
More than 28 percent of the novel new drugs approved by U.S. Food and Drug Administration (FDA) in 2015 were…
Already a member? Log in here
PSA Testing Patterns Vary By Medical Specialty
From – Diagnostic Testing & Emerging Technologies
Prostate specific antigen (PSA) testing varies significantly by physician specialty, according to a research letter published online Feb. 8 in…
Already a member? Log in here
Testing Trends to Watch for in 2016
...
Already a member? Log in here
PCT Effective to ID Invasive Bacterial Infection in Febrile Infants
...
Already a member? Log in here
Simple Patient Info Sheet Not Enough to Dissuade Low-Value Screening
From – Diagnostic Testing & Emerging Technologies
Simple, brief, information sheets are unlikely to change patients’ intentions to participate in low-value screenings, according to a study published online…
Already a member? Log in here